<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">AIDS Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">AIDS Res Ther</journal-id><journal-id journal-id-type="pmc-domain-id">306</journal-id><journal-id journal-id-type="pmc-domain">aidsresther</journal-id><journal-title-group><journal-title>AIDS Research and Therapy</journal-title></journal-title-group><issn pub-type="epub">1742-6405</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10832207</article-id><article-id pub-id-type="pmcid-ver">PMC10832207.1</article-id><article-id pub-id-type="pmcaid">10832207</article-id><article-id pub-id-type="pmcaiid">10832207</article-id><article-id pub-id-type="pmid">38297382</article-id><article-id pub-id-type="doi">10.1186/s12981-024-00594-8</article-id><article-id pub-id-type="publisher-id">594</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Outcomes of antiretroviral treatment for 0-14-year-old children living with HIV in Ganzhou, China, 2006&#8211;2023</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Zeng</surname><given-names initials="T">Ting</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Chen</surname><given-names initials="X">Xin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="XY">Xiao-Yi</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lian</surname><given-names initials="CX">Chao-Xian</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="RR">Rong-Rong</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yu</surname><given-names initials="LL">Li-Ling</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liao</surname><given-names initials="XK">Xiao-Kang</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="DD">Dan-Dan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="YN">Yu-Ning</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Cao</surname><given-names initials="HM">Hong-Min</given-names></name><address><email>2977560371@qq.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01tjgw469</institution-id><institution-id institution-id-type="GRID">grid.440714.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1797 9454</institution-id><institution>Department of Pathogenic Biology, School of Basic Medical Sciences, </institution><institution>Gannan Medical University, </institution></institution-wrap>Ganzhou, China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01tjgw469</institution-id><institution-id institution-id-type="GRID">grid.440714.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1797 9454</institution-id><institution>Department of Epidemiology, School of Public Health and Health Management, </institution><institution>Gannan Medical University, </institution></institution-wrap>Ganzhou, China </aff><aff id="Aff3"><label>3</label>Department of AIDS/STD Control and Prevention, Ganzhou Center for Disease Control and Prevention, No. 6 Zhangjiangbei Avenue, Zhanggong District, Ganzhou, 341000 China </aff></contrib-group><pub-date pub-type="epub"><day>31</day><month>1</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>21</volume><issue-id pub-id-type="pmc-issue-id">452494</issue-id><elocation-id>8</elocation-id><history><date date-type="received"><day>25</day><month>7</month><year>2023</year></date><date date-type="accepted"><day>17</day><month>1</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>31</day><month>01</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>02</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-10-22 15:25:14.743"><day>22</day><month>10</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12981_2024_Article_594.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Studies on antiretroviral therapy (ART) in children living with HIV (CLHIV) are limited due to the small population and low accession rate of ART.</p></sec><sec><title>Methods</title><p id="Par2">All 0-14-year-old CLHIV admitted to the Ganzhou Center for Disease Control and Prevention from January 2006 to June 2023 were included retrospectively. The information of treatment regimens, disease progression, and laboratory tests of the patients under ART were used to explore the outcomes and impacts of long-term ART. The normality of all the data was tested by the Shapiro-Wilk test.</p></sec><sec><title>Results</title><p id="Par3">From 2006 to 2023, 18 CLHIV were reported in Ganzhou. Among them, 11 received ART and were followed up for 60.0&#8201;&#177;&#8201;48.4 months. After receiving ART, the median viral load of them decreased from 89,600 copies/ml to 22 copies/ml (<italic toggle="yes">P</italic>&#8201;=&#8201;0.007), the median CD4<sup>+</sup> T cell count increased from 380.7 cells/&#181;L to 661.9 cells/&#181;L (<italic toggle="yes">P</italic>&#8201;=&#8201;0.028), and the median CD8<sup>+</sup> T cell count decreased from 1065.8 cells/&#181;L to 983.3 cells/&#181;L (<italic toggle="yes">P</italic>&#8201;=&#8201;0.584). The laboratory test results regarding liver function, renal function, blood cell count, and glucolipid metabolism tended to be within normal reference ranges, and the mean height-for-age z-score and weight-for-age z-score increased. However, all the three CLHIV who received cotrimoxazole developed pneumocystis carinii pneumonia, upper respiratory infection, skin lesions, bacterial pneumonia and/or thrush; the mean body-mass-index-for-age z-score decreased from 0.52 to -0.63.</p></sec><sec><title>Conclusion</title><p id="Par4">For CLHIV, ART could effectively inhibit the replication of HIV and improve the immune function of patients. More studies that focus on ART in CLHIV are urgently needed.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>HIV</kwd><kwd>Antiretroviral therapy</kwd><kwd>Children</kwd><kwd>Outcome</kwd><kwd>Ganzhou</kwd></kwd-group><funding-group><award-group><funding-source><institution>Science and Technology Plan of Health Commission of Jiangxi Province</institution></funding-source><award-id>SKJP_220210624</award-id><award-id>SKJP_220218743</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Characteristic Innovation Team Project of Gannan Medical University</institution></funding-source><award-id>TS202001</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Science and Technology Research Project of Department of Education of Jiangxi Province</institution></funding-source><award-id>GJJ211527</award-id><award-id>GJJ2201455</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par5">The first case of human immunodeficiency virus (HIV) in China was reported in 1985 [<xref ref-type="bibr" rid="CR1">1</xref>]. According to the Chinese Center for Disease Control and Prevention (CDC), the newly reported HIV infections increased from 13,258 in 2004 to 104,838 in 2018. Among them, the number of 0-14-year-old children increased from 212 in 2004 to 1,592 in 2018 [<xref ref-type="bibr" rid="CR2">2</xref>]. Previous studies showed that over three-quarters of children living with HIV (CLHIV) in China were infected through mother-to-child transmission (MTCT) [<xref ref-type="bibr" rid="CR3">3</xref>]. CLHIV experienced faster disease progression and higher mortality than adults due to underdeveloped physiological functions [<xref ref-type="bibr" rid="CR4">4</xref>]. Without antiretroviral therapy (ART), more than one-third of them would die in infancy, and more than half of them would die under the age of two years [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par6">ART suppressed viral replication, extending the life expectancy of people living with HIV by promoting immune reconstitution [<xref ref-type="bibr" rid="CR6">6</xref>]. Early initiation of ART significantly decelerated AIDS progression and reduced the risk of death among people living with HIV [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. After early ART, the mortality of CLHIV decreased by 76% within two years, and the progression of AIDS slowed by 75% [<xref ref-type="bibr" rid="CR9">9</xref>]. However, the rate of 0-14-year-old CLHIV who received ART (57%) was much lower than that of adults living with HIV (aged 15 years and older) (77%) [<xref ref-type="bibr" rid="CR10">10</xref>]. Moreover, the group of children with HIV was much smaller than that of adults, which limited the studies on ART in CLHIV.</p><p id="Par7">Most 0-14-year-old CLHIV were infected during the perinatal period, with incomplete immune function and drug metabolism ability [<xref ref-type="bibr" rid="CR11">11</xref>]. Compared with adults living with HIV, they had higher baseline viral loads and required prolonged ART [<xref ref-type="bibr" rid="CR12">12</xref>]. However, the efficacy and toxicity of long-term ART in CLHIV were not clear. Thus, studies exploring the outcomes and impacts of long-term ART in CLHIV are urgently needed to provide theoretical guidance for better treatment.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Ethics approval and consent to participate</title><p id="Par8">The protocol of this study was approved by the Ethics Committee of Gannan Medical University (approval number: 2,021,320; approval date: October 5, 2021). All participants gave written informed consent.</p></sec><sec id="Sec4"><title>Population and data collection</title><p id="Par9">Locating in eastern China, Ganzhou is the largest prefecture of Jiangxi Province, with nearly nine million resident population. In this study, all 0-14-year-old CLHIV who were diagnosed at the Ganzhou CDC from January 2006 to June 2023 were retrospectively included. Information on socio-demographic, follow-up medication, and laboratory test results of all participants available in the China Information System for Disease Control and Prevention were exported and explored.</p><p id="Par10">According to the <italic toggle="yes">Chinese Guidelines for Diagnosis and Treatment of HIV/AIDS</italic> before 2015, CLHIV who initiated ART should meet one of the criteria: (1) 0-1-year-old; (2) 1-3-year-old with CD4<sup>+</sup> T cell count less than 750 cells/&#181;L; (3) 3-14-year-old with CD4<sup>+</sup> T cell count less than 350 cells/&#181;L. After 2015, CLHIV could receive ART voluntarily without any limitation of CD4<sup>+</sup> T cell count. For people living with HIV, the criteria for receiving cotrimoxazole was with CD4<sup>+</sup> T cell count less than 200 cells/&#181;L. In this study, the basic information and outcomes of ART of CLHIV who received ART were explored.</p></sec><sec id="Sec5"><title>Statistical analysis</title><p id="Par11">After testing by the Shapiro-Wilk test, the quantitative data with a normal distribution were described using the means&#8201;&#177;&#8201;standard deviation. In contrast, the quantitative data with a nonnormal distribution were described using the medians (percentage 25, percentage 75). Qualitative data were described using numbers and percentages.</p><p id="Par12">The growth of the study children was measured by height-for-age z-score (HAZ), weight-for-age z-score (WAZ), and body-mass-index-for-age z-score (BAZ) based on the World Health Organization (WHO) growth reference data [<xref ref-type="bibr" rid="CR13">13</xref>]. Since the frequency of laboratory tests varied, the last recorded laboratory test result before ART was considered the pre-ART result, and the last recorded laboratory test result during ART (as of June 2023) was considered the post-ART result. Test values exceeding sensitivity were substituted with sensitivity limits. Differences between the two results were analyzed using a paired t-test or paired rank sum test, depending on the normality of the data distribution. All statistical analyses were performed with the software Statistical Package for Social Sciences (SPSS, version 26, IBM Corporation, Armonk, USA) with a 95% confidence interval. A two-sided <italic toggle="yes">P</italic> value less than 0.05 was considered statistically significant.</p></sec></sec><sec id="Sec6" sec-type="results"><title>Results</title><sec id="Sec7"><title>Characteristics of the study population</title><p id="Par13">From January 2006 to June 2023, a total of 18 0-14-year-old CLHIV who resident in Ganzhou were diagnosed at Ganzhou CDC. Among them, 17 were outpatients with MTCT and one was inpatient with heterosexual transmission; six (33.3%) were males and twelve (66.7%) were females; 11 received ART and seven did not. The mortality rate within two years of diagnosis among patients who received ART was significantly lower than that among patients who did not receive ART (9.1% versus 57.1%, <italic toggle="yes">P</italic>&#8201;=&#8201;0.047).</p><p id="Par14">All 11 0-14-year-old CLHIV receiving ART were enrolled in the study (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). From the results of the first laboratory tests, the mean age of these patients was 73.2&#8201;&#177;&#8201;39.6 mouths, the mean HAZ was &#8722;&#8201;2.28&#8201;&#177;&#8201;2.33, the WAZ was &#8722;&#8201;1.09&#8201;&#177;&#8201;0.92, the mean BAZ was 0.39&#8201;&#177;&#8201;1.27, the median CD4<sup>+</sup> T cell count was 120 (41, 605) cells/&#181;L and the median viral load was 54,600 (2593, 331,250) copies/mL. Among them, 72.7% were WHO clinical stage I and II, and 45.5% had opportunistic infections before starting ART, such as upper respiratory infection, skin lesions, and pneumocystis carinii pneumonia.</p><p id="Par15">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Characteristics of 0-14-year-old children living with HIV at the start of ART in Ganzhou, 2006&#8211;2023</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Patient no.</th><th align="left" colspan="1" rowspan="1">Gender</th><th align="left" colspan="1" rowspan="1">HIV transmission mode</th><th align="left" colspan="1" rowspan="1">Age<break/>(years)</th><th align="left" colspan="1" rowspan="1">Height<break/>(cm)</th><th align="left" colspan="1" rowspan="1">Weight<break/>(kg)</th><th align="left" colspan="1" rowspan="1">CD4 level (cells/&#181;L)</th><th align="left" colspan="1" rowspan="1">Viral load (copies/mL)</th><th align="left" colspan="1" rowspan="1">WHO clinical stage</th><th align="left" colspan="1" rowspan="1">AIDS-related opportunistic infections</th><th align="left" colspan="1" rowspan="1">Cotrimoxazole</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">GZ5F1</td><td align="left" colspan="1" rowspan="1">Female</td><td align="left" colspan="1" rowspan="1">MTCT</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">110</td><td align="left" colspan="1" rowspan="1">18.0</td><td align="left" colspan="1" rowspan="1">110</td><td align="left" colspan="1" rowspan="1">1,790,000</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Not</td></tr><tr><td align="left" colspan="1" rowspan="1">GZ5F2</td><td align="left" colspan="1" rowspan="1">Female</td><td align="left" colspan="1" rowspan="1">MTCT</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">92</td><td align="left" colspan="1" rowspan="1">16.0</td><td align="left" colspan="1" rowspan="1">1292</td><td align="left" colspan="1" rowspan="1">19,600</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Not</td></tr><tr><td align="left" colspan="1" rowspan="1">GZ8F3</td><td align="left" colspan="1" rowspan="1">Female</td><td align="left" colspan="1" rowspan="1">MTCT</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">130</td><td align="left" colspan="1" rowspan="1">25.0</td><td align="left" colspan="1" rowspan="1">605</td><td align="left" colspan="1" rowspan="1">1340</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Not</td></tr><tr><td align="left" colspan="1" rowspan="1">GZ8F4</td><td align="left" colspan="1" rowspan="1">Female</td><td align="left" colspan="1" rowspan="1">MTCT</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">122</td><td align="left" colspan="1" rowspan="1">23.0</td><td align="left" colspan="1" rowspan="1">101</td><td align="left" colspan="1" rowspan="1">89,600</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Not</td></tr><tr><td align="left" colspan="1" rowspan="1">GZ13F5</td><td align="left" colspan="1" rowspan="1">Female</td><td align="left" colspan="1" rowspan="1">HT</td><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">150</td><td align="left" colspan="1" rowspan="1">43.0</td><td align="left" colspan="1" rowspan="1">306</td><td align="left" colspan="1" rowspan="1">158,000</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1">Skin lesions</td><td align="left" colspan="1" rowspan="1">Not</td></tr><tr><td align="left" colspan="1" rowspan="1">GZ1M6</td><td align="left" colspan="1" rowspan="1">Male</td><td align="left" colspan="1" rowspan="1">MTCT</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">65</td><td align="left" colspan="1" rowspan="1">8.0</td><td align="left" colspan="1" rowspan="1">120</td><td align="left" colspan="1" rowspan="1">4230</td><td align="left" colspan="1" rowspan="1">IV</td><td align="left" colspan="1" rowspan="1">Pneumocystis carinii pneumonia; Upper respiratory infection</td><td align="left" colspan="1" rowspan="1">Access</td></tr><tr><td align="left" colspan="1" rowspan="1">GZ2M7</td><td align="left" colspan="1" rowspan="1">Male</td><td align="left" colspan="1" rowspan="1">MTCT</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">66</td><td align="left" colspan="1" rowspan="1">8.0</td><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">851,000</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1">Pneumocystis carinii pneumonia; Upper respiratory infection</td><td align="left" colspan="1" rowspan="1">Not</td></tr><tr><td align="left" colspan="1" rowspan="1">GZ4M8</td><td align="left" colspan="1" rowspan="1">Male</td><td align="left" colspan="1" rowspan="1">MTCT</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">97</td><td align="left" colspan="1" rowspan="1">15.0</td><td align="left" colspan="1" rowspan="1">41</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">III</td><td align="left" colspan="1" rowspan="1">Skin lesions; Upper respiratory infection</td><td align="left" colspan="1" rowspan="1">Access</td></tr><tr><td align="left" colspan="1" rowspan="1">GZ5M9</td><td align="left" colspan="1" rowspan="1">Male</td><td align="left" colspan="1" rowspan="1">MTCT</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">95</td><td align="left" colspan="1" rowspan="1">11.5</td><td align="left" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;20</td><td align="left" colspan="1" rowspan="1">III</td><td align="left" colspan="1" rowspan="1">Bacterial pneumonia; Thrush</td><td align="left" colspan="1" rowspan="1">Access</td></tr><tr><td align="left" colspan="1" rowspan="1">GZ6M10</td><td align="left" colspan="1" rowspan="1">Male</td><td align="left" colspan="1" rowspan="1">MTCT</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">100</td><td align="left" colspan="1" rowspan="1">18.0</td><td align="left" colspan="1" rowspan="1">224</td><td align="left" colspan="1" rowspan="1">3010</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Not</td></tr><tr><td align="left" colspan="1" rowspan="1">GZ8M11</td><td align="left" colspan="1" rowspan="1">Male</td><td align="left" colspan="1" rowspan="1">MTCT</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">130</td><td align="left" colspan="1" rowspan="1">24.0</td><td align="left" colspan="1" rowspan="1">1017</td><td align="left" colspan="1" rowspan="1">112,000</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Not</td></tr></tbody></table><table-wrap-foot><p>HT, heterosexual transmission; MTCT, mother-to-child transmission; /, the patient did not test for viral load; -, the patients did not present with any AIDS-related opportunistic infections</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec8"><title>Treatment and follow-up situation</title><p id="Par16">The median duration of diagnosis to first ART among the 11 0-14-year-old CLHIV was 14 months, ranging from 32 days to six years (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Ten of them (90.9%) received a nationally approved triple-drug regimen in China and one of them received only Stavudine (D4T). Six of them (54.5%) took lamivudine (3TC), zidovudine (AZT), and nevirapine (NVP) as their first treatment regimen.</p><p id="Par17">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>The treatment of 0-14-year-old children living with HIV in Ganzhou, China</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Patient no.</th><th align="left" colspan="1" rowspan="1">Duration of diagnosis to first ART (months)</th><th align="left" colspan="1" rowspan="1">Initial ART regimen</th><th align="left" colspan="1" rowspan="1">Follow-up duration(months)</th><th align="left" colspan="1" rowspan="1">AIDS-related opportunistic infections</th><th align="left" colspan="1" rowspan="1">Cotrimoxazole</th><th align="left" colspan="1" rowspan="1">Current ART regimen</th><th align="left" colspan="1" rowspan="1">Current status</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">GZ5F1</td><td align="left" colspan="1" rowspan="1">32</td><td align="left" colspan="1" rowspan="1">3TC/AZT&#8201;+&#8201;NVP</td><td align="left" colspan="1" rowspan="1">77</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Not</td><td align="left" colspan="1" rowspan="1">3TC/AZT&#8201;+&#8201;NVP</td><td align="left" colspan="1" rowspan="1">Follow-up</td></tr><tr><td align="left" colspan="1" rowspan="1">GZ5F2</td><td align="left" colspan="1" rowspan="1">27</td><td align="left" colspan="1" rowspan="1">3TC&#8201;+&#8201;AZT&#8201;+&#8201;EFV</td><td align="left" colspan="1" rowspan="1">89</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Access</td><td align="left" colspan="1" rowspan="1">3TC&#8201;+&#8201;AZT&#8201;+&#8201;EFV</td><td align="left" colspan="1" rowspan="1">Follow-up</td></tr><tr><td align="left" colspan="1" rowspan="1">GZ8F3</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">3TC&#8201;+&#8201;ABC&#8201;+&#8201;EFV</td><td align="left" colspan="1" rowspan="1">31</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Not</td><td align="left" colspan="1" rowspan="1">3TC/AZT&#8201;+&#8201;EFV</td><td align="left" colspan="1" rowspan="1">Follow-up</td></tr><tr><td align="left" colspan="1" rowspan="1">GZ8F4</td><td align="left" colspan="1" rowspan="1">71</td><td align="left" colspan="1" rowspan="1">3TC&#8201;+&#8201;AZT&#8201;+&#8201;NVP</td><td align="left" colspan="1" rowspan="1">34</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Access</td><td align="left" colspan="1" rowspan="1">3TC/AZT&#8201;+&#8201;NVP</td><td align="left" colspan="1" rowspan="1">Follow-up</td></tr><tr><td align="left" colspan="1" rowspan="1">GZ13F5</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">3TC&#8201;+&#8201;TDF&#8201;+&#8201;EFV</td><td align="left" colspan="1" rowspan="1">28</td><td align="left" colspan="1" rowspan="1">Skin lesions</td><td align="left" colspan="1" rowspan="1">Access</td><td align="left" colspan="1" rowspan="1">3TC&#8201;+&#8201;TDF&#8201;+&#8201;EFV</td><td align="left" colspan="1" rowspan="1">Follow-up</td></tr><tr><td align="left" colspan="1" rowspan="1">GZ1M6</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">3TC&#8201;+&#8201;AZT&#8201;+&#8201;NVP</td><td align="left" colspan="1" rowspan="1">124</td><td align="left" colspan="1" rowspan="1">Bacterial pneumonia; Pneumocystis carinii pneumonia</td><td align="left" colspan="1" rowspan="1">Not</td><td align="left" colspan="1" rowspan="1">3TC&#8201;+&#8201;AZT&#8201;+&#8201;NVP</td><td align="left" colspan="1" rowspan="1">Follow-up</td></tr><tr><td align="left" colspan="1" rowspan="1">GZ2M7</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">3TC&#8201;+&#8201;AZT&#8201;+&#8201;NVP</td><td align="left" colspan="1" rowspan="1">116</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Access</td><td align="left" colspan="1" rowspan="1">3TC&#8201;+&#8201;AZT&#8201;+&#8201;LPV/r</td><td align="left" colspan="1" rowspan="1">Follow-up</td></tr><tr><td align="left" colspan="1" rowspan="1">GZ4M8</td><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">D4T</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Not</td><td align="left" colspan="1" rowspan="1">D4T</td><td align="left" colspan="1" rowspan="1">Dead</td></tr><tr><td align="left" colspan="1" rowspan="1">GZ5M9</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">3TC&#8201;+&#8201;AZT&#8201;+&#8201;NVP</td><td align="left" colspan="1" rowspan="1">129</td><td align="left" colspan="1" rowspan="1">Bacterial pneumonia</td><td align="left" colspan="1" rowspan="1">Not</td><td align="left" colspan="1" rowspan="1">3TC/AZT&#8201;+&#8201;NVP</td><td align="left" colspan="1" rowspan="1">Follow-up</td></tr><tr><td align="left" colspan="1" rowspan="1">GZ6M10</td><td align="left" colspan="1" rowspan="1">69</td><td align="left" colspan="1" rowspan="1">3TC&#8201;+&#8201;AZT&#8201;+&#8201;NVP</td><td align="left" colspan="1" rowspan="1">28</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Not</td><td align="left" colspan="1" rowspan="1">3TC&#8201;+&#8201;AZT&#8201;+&#8201;NVP</td><td align="left" colspan="1" rowspan="1">Follow-up</td></tr><tr><td align="left" colspan="1" rowspan="1">GZ8M11</td><td align="left" colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">3TC&#8201;+&#8201;AZT&#8201;+&#8201;EFV</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Not</td><td align="left" colspan="1" rowspan="1">3TC&#8201;+&#8201;AZT&#8201;+&#8201;EFV</td><td align="left" colspan="1" rowspan="1">Loss to follow-up</td></tr></tbody></table><table-wrap-foot><p>3TC, lamivudine; ABC, abacavir; AZT, zidovudine; D4T, stavudine; EFV, efavirenz; LPV/r, lopinavir/ritonavir; NVP, nevirapine; TDF, tenofovir; -, the patients did not present with any AIDS-related opportunistic infections. The current treatment regimens for deceased and lost-to-follow patients were the final treatment regimens before death or loss of follow-up</p></table-wrap-foot></table-wrap>
</p><p id="Par18">The 11 CLHIV were followed up for one month to 11 years after starting ART, with a mean duration of 60.0&#8201;&#177;&#8201;48.4 months (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). During the follow-up period, the mean rate of lost to follow-up, stopped-taking medicine, and missed doses was 3.1%, 3.2%, and 4.2%, respectively. Four patients took cotrimoxazole, and one of them had skin lesion, while among the seven patients who did not take cotrimoxazole, two of them had bacterial pneumonia and pneumocystis carinii pneumonia. The opportunistic infection rates between these two groups were not significantly different (<italic toggle="yes">P</italic>&#8201;=&#8201;0.721). However, compared with the period prior to ART, the opportunistic infection rate decreased rapidly after one month of ART. During the treatment, patient GZ8F3 changed her regimen due to drug interaction, and patient GZ3M7 switched to the second-line regimen due to virological failure.</p><p id="Par19">As of 2023, one patient died, one patient was lost to follow-up. For the nine patients who had been followed up for more than 28 months, the mean HAZ increased from &#8722;&#8201;2.61&#8201;&#177;&#8201;2.40 to -0.58&#8201;&#177;&#8201;1.62, and the mean WAZ increased from &#8722;&#8201;1.20&#8201;&#177;&#8201;1.01 to -0.25&#8201;&#177;&#8201;1.15. However, compared to the beginning of ART, the mean BAZ decreased from 0.52&#8201;&#177;&#8201;1.34 to -0.63&#8201;&#177;&#8201;1.04 in the last follow-up of this study.</p></sec><sec id="Sec9"><title>Laboratory results</title><p id="Par20">The changing trends of viral load, CD4<sup>+</sup> T cell count, and CD8<sup>+</sup> T cell count were explored among nine 0-14-year-old CLHIV who were followed up for more than 28 months in this study (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). After receiving ART, the patient&#8217;s viral load decreased quickly and then stabilized at a low level, from 89,600 (4230, 851,000) copies/ml at the beginning of ART to 22 (20, 45,500) copies/ml at the last time of follow-up (<italic toggle="yes">P&#8201;=</italic>&#8201;0.007). The CD4<sup>+</sup> T cell count of the CLHIV increased in the early stages of ART and then remained stable, from 380.7&#8201;&#177;&#8201;447.4 cells/&#181;L at the beginning of ART to 661.9&#8201;&#177;&#8201;316.2 cells/&#181;L at the last time of follow-up (<italic toggle="yes">P&#8201;=</italic>&#8201;0.028). The CD8<sup>+</sup> T cell count showed insignificant changing trends, from 1065.8&#8201;&#177;&#8201;687.2 cells/&#181;L at the beginning of ART to 983.3&#8201;&#177;&#8201;311.0 cells/&#181;L at the last time of follow-up (<italic toggle="yes">P&#8201;=</italic>&#8201;0.584).</p><p id="Par21">After receiving ART, the white blood cell count and the plasma creatinine significantly increased (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05); the platelet count, hemoglobin, triglycerides, total cholesterol, glucose, alanine aminotransferase, and total bilirubin slightly increased (<italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.05), while the aspartate aminotransferase slightly decreased (<italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.05).</p></sec></sec><sec id="Sec10" sec-type="discussion"><title>Discussion</title><p id="Par22">In this study, the ART acquisition rate among 0-14-year-old CLHIV in Ganzhou from 2006 to 2023 was 61.1%. The mortality rate in children without ART was significantly higher than in children with ART (<italic toggle="yes">P</italic>&#8201;=&#8201;0.047). Most CLHIV achieved viral suppression within the first year of ART and regained partial immune function, with fewer opportunistic infections. In addition, we further used growth metrics (HAZ, WAZ, and BAZ) to evaluate the treatment effect of ART in 0-14-year-old CLHIV and found that growth recovery was not significant in them. These findings suggest that ART can reduce mortality and slow the progression of the disease in 0-14-year-old CLHIV. Therefore, CLHIV should be diagnosed and treated as early as possible. During treatment, doctors and treatment organizations should pay attention to the children&#8217;s growth indicators and formulate appropriate nutritional support programs to help CLHIV achieve the best possible therapeutic outcomes.</p><p id="Par23">Among the WHO-recommended first-line antiretroviral regimens for CLHIV, the non-nucleoside drug NVP was favored in resource-limited areas due to its heat resistance, fixed-dose combinations, affordability, and safety [<xref ref-type="bibr" rid="CR14">14</xref>]. Several studies had shown that NVP-based ART lowers clinical events in children, but older children and those with higher CD4 counts may develop a rash [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. In this study, 54.5% of the CLHIV chose NVP-based ART, with 66.7% achieving complete viral suppression in 3&#8211;16 months, but some had bacterial pneumonia. Extended NVP exposure led to high resistance in perinatally infected patients [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. In the present study, patient GZ2M7 with primary NVP resistance had unsuppressed viral load and low CD4<sup>+</sup> T cell count while on the NVP regimen but switching to a Lopinavir/ritonavir-based regimen improved viral suppression and CD4<sup>+</sup> T cell count. Consequently, for maternal women living with HIV and HIV perinatally infected children, drug resistance testing before initiating ART might provide useful information to develop optimal treatment regimens.</p><p id="Par24">Previous studies had shown that the toxic effects of ART can lead to hepatocellular damage, renal abnormalities, and disorders of glucolipid metabolism in adult patients [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. However, the toxic effects in pediatric patients were unknown. This study innovatively used blood, renal function, glucolipid metabolism, and liver function parameters to evaluate drug toxicity in CLHIV undergoing ART for a prolonged period. The results showed that the ART&#8217;s impact on CLHIV&#8217;s blood cell counts and glucolipid metabolism were transient and resolved spontaneously, and the function of the renal and kidney gradually improved and stabilized as the ART duration was prolonged. Study has revealed that cotrimoxazole significantly improves the survival rate of adult people living with HIV by reducing the risk of contracting HIV-related diseases [<xref ref-type="bibr" rid="CR20">20</xref>]. Our study found that cotrimoxazole before ART did not prevent infections effectively but reduced opportunistic infections during ART. These findings suggest potential differences in antiviral regimen toxicity between pediatric and adult patients, warranting further in-depth research.</p></sec><sec id="Sec11" sec-type="conclusion"><title>Conclusion</title><p id="Par25">In the present study, the outcomes and impacts of long-term ART were explored by comparing the differences in the treatment regimen, disease progression, and laboratory test results among 11 0-14-year-old CLHIV in Ganzhou, China. The results showed that ART could effectively inhibit the replication of HIV and improve the immune function, liver function, renal function, blood cell count, and glucolipid metabolism of the patients. However, the administration of cotrimoxazole prior to ART initiation did not effectively prevent opportunistic infections, and the recovery of growth metrics in children is not significant. More studies focusing on ART in CLHIV are urgently needed to help them achieve better outcomes.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>3TC</term><def><p id="Par29">Lamivudine</p></def></def-item><def-item><term>ART</term><def><p id="Par30">Antiretroviral therapy</p></def></def-item><def-item><term>AZT</term><def><p id="Par31">Zidovudine</p></def></def-item><def-item><term>BAZ</term><def><p id="Par32">Body-mass-index-for-age z-score</p></def></def-item><def-item><term>CDC</term><def><p id="Par33">Center for Disease Control and Prevention</p></def></def-item><def-item><term>D4T</term><def><p id="Par34">Stavudine</p></def></def-item><def-item><term>EFV</term><def><p id="Par35">Efavirenz</p></def></def-item><def-item><term>HAZ</term><def><p id="Par36">Height-for-age z-score</p></def></def-item><def-item><term>HIV</term><def><p id="Par37">Human immunodeficiency virus</p></def></def-item><def-item><term>LPV/r</term><def><p id="Par38">Lopinavir/ritonavir</p></def></def-item><def-item><term>MTCT</term><def><p id="Par39">Mother-to-child transmission</p></def></def-item><def-item><term>NVP</term><def><p id="Par40">Nevirapine</p></def></def-item><def-item><term>WAZ</term><def><p id="Par41">Weight-for-age z-score</p></def></def-item><def-item><term>WHO</term><def><p id="Par42">World Health Organization</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Ting Zeng and Xin Chen contributed equally to this study.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank all the children for participating in the study.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>TZ and HMC conceived and designed the study. XC, XYZ, CXL, RRY, LLY, and XKL collected the original records. TZ, XC, DDH, and YNZ analyzed the data and drafted the paper. HMC critically revised the paper. All authors read and approved the final paper.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by the Science and Technology Plan of Health Commission of Jiangxi Province (SKJP_220210624, SKJP_220218743), the Science and Technology Research Project of Department of Education of Jiangxi Province (GJJ2201455, GJJ211527), and the Characteristic Innovation Team Project of Gannan Medical University (TS202001). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data supporting this study&#8217;s findings are available from the corresponding author (2977560371@qq.com) upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar2"><title>Consent for publication</title><p id="Par28">Not applicable.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par27">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>ES</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K</given-names></name><name name-style="western"><surname>Lu</surname><given-names>P</given-names></name><name name-style="western"><surname>Chan</surname><given-names>LL</given-names></name></person-group><article-title>HIV infection and AIDS in China, 1985 through 1994</article-title><source>Am J Public Health</source><year>1996</year><volume>86</volume><issue>8</issue><fpage>1116</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.2105/AJPH.86.8_Pt_1.1116</pub-id><pub-id pub-id-type="pmid">8712271</pub-id><pub-id pub-id-type="pmcid">PMC1380623</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Chinese Center for Disease Control and Prevention. Public Health Sciences Data Center: Statutory reporting of infectious diseases. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.phsciencedata.cn/Share/index.jsp">https://www.phsciencedata.cn/Share/index.jsp</ext-link>. Accessed 19 Oct 2023.</mixed-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>F</given-names></name><name name-style="western"><surname>Liang</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Lu</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Hu</surname><given-names>YF</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zou</surname><given-names>XW</given-names></name><name name-style="western"><surname>Ma</surname><given-names>YH</given-names></name><name name-style="western"><surname>Lin</surname><given-names>SF</given-names></name></person-group><article-title>Effects of antiretroviral therapy and HIV exposure in Utero on adverse pregnancy and infant outcomes: a prospective cohort study in Guangzhou, China</article-title><source>Biomed Environ Sci</source><year>2019</year><volume>32</volume><issue>10</issue><fpage>719</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">31843042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3967/bes2019.092</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tovo</surname><given-names>PA</given-names></name><name name-style="western"><surname>de Martino</surname><given-names>M</given-names></name><name name-style="western"><surname>Gabiano</surname><given-names>C</given-names></name><name name-style="western"><surname>Cappello</surname><given-names>N</given-names></name><name name-style="western"><surname>D&#8217;Elia</surname><given-names>R</given-names></name><name name-style="western"><surname>Loy</surname><given-names>A</given-names></name><name name-style="western"><surname>Plebani</surname><given-names>A</given-names></name><name name-style="western"><surname>Zuccotti</surname><given-names>GV</given-names></name><name name-style="western"><surname>Dallacasa</surname><given-names>P</given-names></name><name name-style="western"><surname>Ferraris</surname><given-names>G</given-names></name></person-group><article-title>Prognostic factors and survival in children with perinatal HIV-1 infection. The Italian Register for HIV infections in Children</article-title><source>Lancet</source><year>1992</year><volume>339</volume><issue>8804</issue><fpage>1249</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/0140-6736(92)91592-V</pub-id><pub-id pub-id-type="pmid">1349667</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Newell</surname><given-names>M-L</given-names></name><name name-style="western"><surname>Coovadia</surname><given-names>H</given-names></name><name name-style="western"><surname>Cortina-Borja</surname><given-names>M</given-names></name><name name-style="western"><surname>Rollins</surname><given-names>N</given-names></name><name name-style="western"><surname>Gaillard</surname><given-names>P</given-names></name><name name-style="western"><surname>Dabis</surname><given-names>F</given-names></name></person-group><article-title>Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis</article-title><source>Lancet</source><year>2004</year><volume>364</volume><issue>9441</issue><fpage>1236</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(04)17140-7</pub-id><pub-id pub-id-type="pmid">15464184</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shiau</surname><given-names>S</given-names></name><name name-style="western"><surname>Abrams</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Arpadi</surname><given-names>SM</given-names></name><name name-style="western"><surname>Kuhn</surname><given-names>L</given-names></name></person-group><article-title>Early antiretroviral therapy in HIV-infected infants: can it lead to HIV remission?</article-title><source>Lancet HIV</source><year>2018</year><volume>5</volume><issue>5</issue><fpage>e250</fpage><lpage>e8</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(18)30012-2</pub-id><pub-id pub-id-type="pmid">29739699</pub-id><pub-id pub-id-type="pmcid">PMC7487171</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ndung&#8217;u</surname><given-names>T</given-names></name><name name-style="western"><surname>McCune</surname><given-names>JM</given-names></name><name name-style="western"><surname>Deeks</surname><given-names>SG</given-names></name></person-group><article-title>Why and where an HIV cure is needed and how it might be achieved</article-title><source>Nature</source><year>2019</year><volume>576</volume><issue>7787</issue><fpage>397</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1841-8</pub-id><pub-id pub-id-type="pmid">31853080</pub-id><pub-id pub-id-type="pmcid">PMC8052635</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maartens</surname><given-names>G</given-names></name><name name-style="western"><surname>Celum</surname><given-names>C</given-names></name><name name-style="western"><surname>Lewin</surname><given-names>SR</given-names></name></person-group><article-title>HIV infection: epidemiology, pathogenesis, treatment, and prevention</article-title><source>Lancet</source><year>2014</year><volume>384</volume><issue>9939</issue><fpage>258</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(14)60164-1</pub-id><pub-id pub-id-type="pmid">24907868</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Violari</surname><given-names>A</given-names></name><name name-style="western"><surname>Cotton</surname><given-names>MF</given-names></name><name name-style="western"><surname>Gibb</surname><given-names>DM</given-names></name><name name-style="western"><surname>Babiker</surname><given-names>AG</given-names></name><name name-style="western"><surname>Steyn</surname><given-names>J</given-names></name><name name-style="western"><surname>Madhi</surname><given-names>SA</given-names></name><name name-style="western"><surname>Jean-Philippe</surname><given-names>P</given-names></name><name name-style="western"><surname>McIntyre</surname><given-names>JA</given-names></name></person-group><article-title>Early antiretroviral therapy and mortality among HIV-infected infants</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><issue>21</issue><fpage>2233</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0800971</pub-id><pub-id pub-id-type="pmid">19020325</pub-id><pub-id pub-id-type="pmcid">PMC2950021</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">World Health Organization. Global HIV &amp; AIDS statistics &#8212; Fact sheet. Geneva: UNAIDS <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.unaids.org/en/resources/fact-sheet">https://www.unaids.org/en/resources/fact-sheet</ext-link>. Accessed 19 Oct 2023.</mixed-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kourtis</surname><given-names>AP</given-names></name><name name-style="western"><surname>Lee</surname><given-names>FK</given-names></name><name name-style="western"><surname>Abrams</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Jamieson</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Bulterys</surname><given-names>M</given-names></name></person-group><article-title>Mother-to-child transmission of HIV-1: timing and implications for prevention</article-title><source>Lancet Infect Dis</source><year>2006</year><volume>6</volume><issue>11</issue><fpage>726</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(06)70629-6</pub-id><pub-id pub-id-type="pmid">17067921</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Rossum</surname><given-names>AMC</given-names></name><name name-style="western"><surname>Fraaij</surname><given-names>PLA</given-names></name><name name-style="western"><surname>de Groot</surname><given-names>R</given-names></name></person-group><article-title>Efficacy of highly active antiretroviral therapy in HIV-1 infected children</article-title><source>Lancet Infect Dis</source><year>2002</year><volume>2</volume><issue>2</issue><fpage>93</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(02)00183-4</pub-id><pub-id pub-id-type="pmid">11901656</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">World Health Organization. Child growth standards. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/tools/child-growth-standards">https://www.who.int/tools/child-growth-standards</ext-link>. Accessed 19 Oct 2023.</mixed-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Violari</surname><given-names>A</given-names></name><name name-style="western"><surname>Lindsey</surname><given-names>JC</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>MD</given-names></name><name name-style="western"><surname>Mujuru</surname><given-names>HA</given-names></name><name name-style="western"><surname>Barlow-Mosha</surname><given-names>L</given-names></name><name name-style="western"><surname>Kamthunzi</surname><given-names>P</given-names></name><name name-style="western"><surname>Chi</surname><given-names>BH</given-names></name><name name-style="western"><surname>Cotton</surname><given-names>MF</given-names></name><name name-style="western"><surname>Moultrie</surname><given-names>H</given-names></name><name name-style="western"><surname>Khadse</surname><given-names>S</given-names></name><etal/></person-group><article-title>Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><issue>25</issue><fpage>2380</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1113249</pub-id><pub-id pub-id-type="pmid">22716976</pub-id><pub-id pub-id-type="pmcid">PMC3443859</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luzuriaga</surname><given-names>K</given-names></name><name name-style="western"><surname>Bryson</surname><given-names>Y</given-names></name><name name-style="western"><surname>McSherry</surname><given-names>G</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>J</given-names></name><name name-style="western"><surname>Stechenberg</surname><given-names>B</given-names></name><name name-style="western"><surname>Scott</surname><given-names>G</given-names></name><name name-style="western"><surname>Lamson</surname><given-names>M</given-names></name><name name-style="western"><surname>Cort</surname><given-names>S</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>JL</given-names></name></person-group><article-title>Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children</article-title><source>J Infect Dis</source><year>1996</year><volume>174</volume><issue>4</issue><fpage>713</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/infdis/174.4.713</pub-id><pub-id pub-id-type="pmid">8843207</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Leth</surname><given-names>F</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>S</given-names></name><name name-style="western"><surname>Grinsztejn</surname><given-names>B</given-names></name><name name-style="western"><surname>Wilkins</surname><given-names>E</given-names></name><name name-style="western"><surname>Lazanas</surname><given-names>MK</given-names></name><name name-style="western"><surname>Lange</surname><given-names>JMA</given-names></name><name name-style="western"><surname>Montaner</surname><given-names>J</given-names></name></person-group><article-title>The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART</article-title><source>AIDS</source><year>2005</year><volume>19</volume><issue>5</issue><fpage>463</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1097/01.aids.0000162334.12815.5b</pub-id><pub-id pub-id-type="pmid">15764851</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bardsley-Elliot</surname><given-names>A</given-names></name><name name-style="western"><surname>Perry</surname><given-names>CM</given-names></name></person-group><article-title>Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection</article-title><source>Paediatr Drugs</source><year>2000</year><volume>2</volume><issue>5</issue><fpage>373</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.2165/00128072-200002050-00005</pub-id><pub-id pub-id-type="pmid">11022799</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>Research progress of HIV-1 epidemic situation, treatment and drug resistance in Jiangxi</article-title><source>J Gannan Med Univ</source><year>2023</year><volume>43</volume><issue>02</issue><fpage>182</fpage><lpage>7</lpage></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kesselring</surname><given-names>AM</given-names></name><name name-style="western"><surname>Wit</surname><given-names>FW</given-names></name><name name-style="western"><surname>Sabin</surname><given-names>CA</given-names></name><name name-style="western"><surname>Lundgren</surname><given-names>JD</given-names></name><name name-style="western"><surname>Gill</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Gatell</surname><given-names>JM</given-names></name><name name-style="western"><surname>Rauch</surname><given-names>A</given-names></name><name name-style="western"><surname>Montaner</surname><given-names>JS</given-names></name><name name-style="western"><surname>de Wolf</surname><given-names>F</given-names></name><name name-style="western"><surname>Reiss</surname><given-names>P</given-names></name><etal/></person-group><article-title>Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy</article-title><source>AIDS</source><year>2009</year><volume>23</volume><issue>13</issue><fpage>1689</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e32832d3b54</pub-id><pub-id pub-id-type="pmid">19487907</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nunn</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Mwaba</surname><given-names>P</given-names></name><name name-style="western"><surname>Chintu</surname><given-names>C</given-names></name><name name-style="western"><surname>Mwinga</surname><given-names>A</given-names></name><name name-style="western"><surname>Darbyshire</surname><given-names>JH</given-names></name><name name-style="western"><surname>Zumla</surname><given-names>A</given-names></name></person-group><article-title>Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial</article-title><source>BMJ</source><year>2008</year><volume>337</volume><fpage>a257</fpage><pub-id pub-id-type="doi">10.1136/bmj.a257</pub-id><pub-id pub-id-type="pmid">18617486</pub-id><pub-id pub-id-type="pmcid">PMC2656923</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>